ACC017 vs Cabotegravir/rilpivirine (Cabenuva)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

HIV

Shared mechanism: HIV integrase · full HIV pipeline

ACC017

Developed by Jiangsu Aidea Pharmaceutical Group

Phase 3 in HIVsmall molecule
Partial signal

NCT06719310 · Phase 1/2 · completed

The first stage of this study randomly assigned patients to ACC017 or placebo under double-blind conditions, a strong design, and its primary endpoints include the proportion of patients reaching an undetectable HIV-1 viral load, a disease-defining measure for HIV therapy. However, results have not yet been posted, so whether the drug met that goal is not yet known.

Next expected readout: June 2027 · NCT07711210 (registry estimate)

Reported efficacy

Report the incidence, severity and seriousness of adverse events, and the relationship between drug and AE (Day 1- Day 11); HIV-1 RNA viral load change from baseline (Day 11); Proportion of patients with HIV-1 RNA viral load <50 copies/mL (Day 29); Pharmacokinetics parameter: Cτ,ss (Day 10, Day 29); Pharmacokinetics parameter: Cmin,ss (Day 10); Pharmacokinetics parameter: Cmax,ss (Day 10); Pharmacokinetics parameter: AUC0-τ,ss (Day 1- Day 10); Pharmacokinetics parameter: Tmax,ss (Day 1-Day 10); Pharmacokinetics parameter: MRT0-τ,ss (Day 1-Day 10): The mean decrease in the groups ranged from 1.44 to 2.34 log 10 copies/mL and none of the participants experienced viral breakthrough. A total of 86.11% of the participants had HIV-RNA of less than 50 copies/mL at day 29. (not_applicable)

Result source: NCT06719310

Cabotegravir/rilpivirine (Cabenuva)

Marketed by GlaxoSmithKline

Approved in HIVsmall molecule
Weak signal

NCT05917509 · Phase 3 · completed

The 171 participants were assigned to active treatment groups without randomization or blinding, which limits the reliability of comparisons between the regimens. The primary outcomes measured virologic suppression. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: March 2027 · NCT06411223 (registry estimate)

Reported efficacy

Percentage of Participants With Plasma Human Immunodeficiency Virus-ribonucleic Acid (HIV-RNA) >=50 Copies Per Milliliter (c/mL) as Per Food and Drug Administration (FDA) Snapshot Algorithm at Week 48: HIV-1 RNA >=50 copies/mL (FDA Snapshot) at Week 48, cabotegravir LA + rilpivirine LA every 8 weeks vs every 4 weeks: 1.7% vs 1.0%, adjusted difference 0.8% (95% CI -0.6 to 2.2); non-inferior against the 4% margin (CT.gov posted results). (met)

Result source: NCT03299049

Results for HIV

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointACC017Cabotegravir/​rilpivirine (Cabenuva)
HIV-1 RNA below 50 copies/mL (week 48)—Trial running · NCT0771122394% vs 91%vs CAB 30 mg+ABC/3TCIM-Q4W · wk 32 · n 115NCT02120352
125 other results
  • 95% vs 91% IM-Q8W · wk 32 · n 115 · Phase 2 · primary NCT02120352
  • 80% vs 71% 30 mg · wk 48 · n 60 · Phase 2 · primary NCT01641809
  • 87% vs 71% 60 mg · wk 48 · n 61 · Phase 2 · primary NCT01641809
  • 80% vs 71% 10 mg · wk 48 · n 60 · Phase 2 · primary NCT01641809
  • 52% vs 0% 30 mg · wk 312 · n 60 · Phase 2 · secondary NCT01641809
  • 60% vs 0% 30 mg · wk 300 · n 60 · Phase 2 · secondary NCT01641809
  • 62% vs 0% 30 mg · wk 288 · n 60 · Phase 2 · secondary NCT01641809
  • 62% vs 0% 30 mg · wk 276 · n 60 · Phase 2 · secondary NCT01641809
  • 62% vs 0% 30 mg · wk 264 · n 60 · Phase 2 · secondary NCT01641809
  • 62% vs 0% 30 mg · wk 252 · n 60 · Phase 2 · secondary NCT01641809
  • 62% vs 0% 30 mg · wk 240 · n 60 · Phase 2 · secondary NCT01641809
  • 63% vs 0% 30 mg · wk 228 · n 60 · Phase 2 · secondary NCT01641809
  • 63% vs 0% 30 mg · wk 216 · n 60 · Phase 2 · secondary NCT01641809
  • 62% vs 0% 30 mg · wk 204 · n 60 · Phase 2 · secondary NCT01641809
  • 65% vs 0% 30 mg · wk 192 · n 60 · Phase 2 · secondary NCT01641809
  • 67% vs 0% 30 mg · wk 180 · n 60 · Phase 2 · secondary NCT01641809
  • 65% vs 0% 30 mg · wk 168 · n 60 · Phase 2 · secondary NCT01641809
  • 63% vs 0% 30 mg · wk 156 · n 60 · Phase 2 · secondary NCT01641809
  • 67% vs 0% 30 mg · wk 144 · n 60 · Phase 2 · secondary NCT01641809
  • 70% vs 0% 30 mg · wk 132 · n 60 · Phase 2 · secondary NCT01641809
  • 73% vs 0% 30 mg · wk 120 · n 60 · Phase 2 · secondary NCT01641809
  • 72% vs 0% 30 mg · wk 108 · n 60 · Phase 2 · secondary NCT01641809
  • 75% vs 63% 30 mg · wk 96 · n 60 · Phase 2 · secondary NCT01641809
  • 85% vs 83% 30 mg · wk 96 · n 53 · Phase 2 · secondary NCT01641809
  • 75% vs 68% 30 mg · wk 84 · n 60 · Phase 2 · secondary NCT01641809
  • 85% vs 89% 30 mg · wk 84 · n 53 · Phase 2 · secondary NCT01641809
  • 73% vs 68% 30 mg · wk 72 · n 60 · Phase 2 · secondary NCT01641809
  • 83% vs 89% 30 mg · wk 72 · n 53 · Phase 2 · secondary NCT01641809
  • 73% vs 68% 30 mg · wk 60 · n 60 · Phase 2 · secondary NCT01641809
  • 83% vs 89% 30 mg · wk 60 · n 53 · Phase 2 · secondary NCT01641809
  • 80% vs 71% 30 mg · wk 48 · n 60 · Phase 2 · secondary NCT01641809
  • 91% vs 94% 30 mg · wk 48 · n 53 · Phase 2 · secondary NCT01641809
  • 82% vs 68% 30 mg · wk 40 · n 60 · Phase 2 · secondary NCT01641809
  • 92% vs 89% 30 mg · wk 40 · n 53 · Phase 2 · secondary NCT01641809
  • 82% vs 71% 30 mg · wk 36 · n 60 · Phase 2 · secondary NCT01641809
  • 92% vs 94% 30 mg · wk 36 · n 53 · Phase 2 · secondary NCT01641809
  • 80% vs 69% 30 mg · wk 32 · n 60 · Phase 2 · secondary NCT01641809
  • 91% vs 91% 30 mg · wk 32 · n 53 · Phase 2 · secondary NCT01641809
  • 78% vs 69% 30 mg · wk 28 · n 60 · Phase 2 · secondary NCT01641809
  • 89% vs 91% 30 mg · wk 28 · n 53 · Phase 2 · secondary NCT01641809
  • 75% vs 66% 30 mg · wk 26 · n 60 · Phase 2 · secondary NCT01641809
  • 85% vs 87% 30 mg · wk 26 · n 53 · Phase 2 · secondary NCT01641809
  • 85% vs 74% 30 mg · wk 24 · n 60 · Phase 2 · secondary NCT01641809
  • 94% vs 96% 30 mg · wk 24 · n 53 · Phase 2 · secondary NCT01641809
  • 70% vs 0% 60 mg · wk 312 · n 61 · Phase 2 · secondary NCT01641809
  • 70% vs 0% 60 mg · wk 300 · n 61 · Phase 2 · secondary NCT01641809
  • 74% vs 0% 60 mg · wk 288 · n 61 · Phase 2 · secondary NCT01641809
  • 70% vs 0% 60 mg · wk 276 · n 61 · Phase 2 · secondary NCT01641809
  • 75% vs 0% 60 mg · wk 264 · n 61 · Phase 2 · secondary NCT01641809
  • 75% vs 0% 60 mg · wk 252 · n 61 · Phase 2 · secondary NCT01641809
  • 74% vs 0% 60 mg · wk 240 · n 61 · Phase 2 · secondary NCT01641809
  • 75% vs 0% 60 mg · wk 228 · n 61 · Phase 2 · secondary NCT01641809
  • 77% vs 0% 60 mg · wk 216 · n 61 · Phase 2 · secondary NCT01641809
  • 75% vs 0% 60 mg · wk 204 · n 61 · Phase 2 · secondary NCT01641809
  • 74% vs 0% 60 mg · wk 192 · n 61 · Phase 2 · secondary NCT01641809
  • 75% vs 0% 60 mg · wk 180 · n 61 · Phase 2 · secondary NCT01641809
  • 75% vs 0% 60 mg · wk 168 · n 61 · Phase 2 · secondary NCT01641809
  • 80% vs 0% 60 mg · wk 156 · n 61 · Phase 2 · secondary NCT01641809
  • 77% vs 0% 60 mg · wk 144 · n 61 · Phase 2 · secondary NCT01641809
  • 80% vs 0% 60 mg · wk 132 · n 61 · Phase 2 · secondary NCT01641809
  • 80% vs 0% 60 mg · wk 120 · n 61 · Phase 2 · secondary NCT01641809
  • 80% vs 0% 60 mg · wk 108 · n 61 · Phase 2 · secondary NCT01641809
  • 84% vs 63% 60 mg · wk 96 · n 61 · Phase 2 · secondary NCT01641809
  • 93% vs 83% 60 mg · wk 96 · n 55 · Phase 2 · secondary NCT01641809
  • 85% vs 68% 60 mg · wk 84 · n 61 · Phase 2 · secondary NCT01641809
  • 95% vs 89% 60 mg · wk 84 · n 55 · Phase 2 · secondary NCT01641809
  • 85% vs 68% 60 mg · wk 72 · n 61 · Phase 2 · secondary NCT01641809
  • 95% vs 89% 60 mg · wk 72 · n 55 · Phase 2 · secondary NCT01641809
  • 85% vs 68% 60 mg · wk 60 · n 61 · Phase 2 · secondary NCT01641809
  • 95% vs 89% 60 mg · wk 60 · n 55 · Phase 2 · secondary NCT01641809
  • 87% vs 71% 60 mg · wk 48 · n 61 · Phase 2 · secondary NCT01641809
  • 96% vs 94% 60 mg · wk 48 · n 55 · Phase 2 · secondary NCT01641809
  • 85% vs 68% 60 mg · wk 40 · n 61 · Phase 2 · secondary NCT01641809
  • 95% vs 89% 60 mg · wk 40 · n 55 · Phase 2 · secondary NCT01641809
  • 85% vs 71% 60 mg · wk 36 · n 61 · Phase 2 · secondary NCT01641809
  • 95% vs 94% 60 mg · wk 36 · n 55 · Phase 2 · secondary NCT01641809
  • 87% vs 69% 60 mg · wk 32 · n 61 · Phase 2 · secondary NCT01641809
  • 96% vs 91% 60 mg · wk 32 · n 55 · Phase 2 · secondary NCT01641809
  • 85% vs 69% 60 mg · wk 28 · n 61 · Phase 2 · secondary NCT01641809
  • 95% vs 91% 60 mg · wk 28 · n 55 · Phase 2 · secondary NCT01641809
  • 85% vs 66% 60 mg · wk 26 · n 61 · Phase 2 · secondary NCT01641809
  • 95% vs 87% 60 mg · wk 26 · n 55 · Phase 2 · secondary NCT01641809
  • 87% vs 74% 60 mg · wk 24 · n 61 · Phase 2 · secondary NCT01641809
  • 96% vs 96% 60 mg · wk 24 · n 55 · Phase 2 · secondary NCT01641809
  • 52% vs 0% 10 mg · wk 312 · n 60 · Phase 2 · secondary NCT01641809
  • 52% vs 0% 10 mg · wk 300 · n 60 · Phase 2 · secondary NCT01641809
  • 50% vs 0% 10 mg · wk 288 · n 60 · Phase 2 · secondary NCT01641809
  • 52% vs 0% 10 mg · wk 276 · n 60 · Phase 2 · secondary NCT01641809
  • 53% vs 0% 10 mg · wk 264 · n 60 · Phase 2 · secondary NCT01641809
  • 52% vs 0% 10 mg · wk 252 · n 60 · Phase 2 · secondary NCT01641809
  • 50% vs 0% 10 mg · wk 240 · n 60 · Phase 2 · secondary NCT01641809
  • 53% vs 0% 10 mg · wk 228 · n 60 · Phase 2 · secondary NCT01641809
  • 55% vs 0% 10 mg · wk 216 · n 60 · Phase 2 · secondary NCT01641809
  • 55% vs 0% 10 mg · wk 204 · n 60 · Phase 2 · secondary NCT01641809
  • 57% vs 0% 10 mg · wk 192 · n 60 · Phase 2 · secondary NCT01641809
  • 58% vs 0% 10 mg · wk 180 · n 60 · Phase 2 · secondary NCT01641809
  • 57% vs 0% 10 mg · wk 168 · n 60 · Phase 2 · secondary NCT01641809
  • 58% vs 0% 10 mg · wk 156 · n 60 · Phase 2 · secondary NCT01641809
  • 58% vs 0% 10 mg · wk 144 · n 60 · Phase 2 · secondary NCT01641809
  • 62% vs 0% 10 mg · wk 132 · n 60 · Phase 2 · secondary NCT01641809
  • 65% vs 0% 10 mg · wk 120 · n 60 · Phase 2 · secondary NCT01641809
  • 68% vs 0% 10 mg · wk 108 · n 60 · Phase 2 · secondary NCT01641809
  • 68% vs 63% 10 mg · wk 96 · n 60 · Phase 2 · secondary NCT01641809
  • 79% vs 83% 10 mg · wk 96 · n 52 · Phase 2 · secondary NCT01641809
  • 72% vs 68% 10 mg · wk 84 · n 60 · Phase 2 · secondary NCT01641809
  • 83% vs 89% 10 mg · wk 84 · n 52 · Phase 2 · secondary NCT01641809
  • 72% vs 68% 10 mg · wk 72 · n 60 · Phase 2 · secondary NCT01641809
  • 83% vs 89% 10 mg · wk 72 · n 52 · Phase 2 · secondary NCT01641809
  • 78% vs 68% 10 mg · wk 60 · n 60 · Phase 2 · secondary NCT01641809
  • 90% vs 89% 10 mg · wk 60 · n 52 · Phase 2 · secondary NCT01641809
  • 80% vs 71% 10 mg · wk 48 · n 60 · Phase 2 · secondary NCT01641809
  • 92% vs 94% 10 mg · wk 48 · n 52 · Phase 2 · secondary NCT01641809
  • 83% vs 68% 10 mg · wk 40 · n 60 · Phase 2 · secondary NCT01641809
  • 96% vs 89% 10 mg · wk 40 · n 52 · Phase 2 · secondary NCT01641809
  • 85% vs 71% 10 mg · wk 36 · n 60 · Phase 2 · secondary NCT01641809
  • 98% vs 94% 10 mg · wk 36 · n 52 · Phase 2 · secondary NCT01641809
  • 83% vs 69% 10 mg · wk 32 · n 60 · Phase 2 · secondary NCT01641809
  • 96% vs 91% 10 mg · wk 32 · n 52 · Phase 2 · secondary NCT01641809
  • 85% vs 69% 10 mg · wk 28 · n 60 · Phase 2 · secondary NCT01641809
  • 98% vs 91% 10 mg · wk 28 · n 52 · Phase 2 · secondary NCT01641809
  • 78% vs 66% 10 mg · wk 26 · n 60 · Phase 2 · secondary NCT01641809
  • 90% vs 87% 10 mg · wk 26 · n 52 · Phase 2 · secondary NCT01641809
  • 87% vs 74% 10 mg · wk 24 · n 60 · Phase 2 · secondary NCT01641809
  • 96% vs 96% 10 mg · wk 24 · n 52 · Phase 2 · secondary NCT01641809
  • 98% vs 100% Q2M · wk 48 · n 90 · Phase 2 · secondary NCT03639311
HIV-1 RNA 50 copies/mL or more (week 48)—Trial running · NCT077112230% vs 0%vs DTG + RPVQ2M · wk 48 · n 90NCT03639311
CD4 count, change (week 48)—Trial running · NCT07711223270.6 vs 369.9vs CAB 30 mg+ABC/3TCIM-Q4W · wk 96 · n 108NCT02120352
36 other results
  • 263.7 vs 346.1 IM-Q4W · wk 32 · n 108 · Phase 2 · secondary NCT02120352
  • 257.5 vs 369.9 IM-Q8W · wk 96 · n 112 · Phase 2 · secondary NCT02120352
  • 264.4 vs 346.1 IM-Q8W · wk 32 · n 112 · Phase 2 · secondary NCT02120352
  • 267.5 vs 281.7 30 mg · wk 96 · n 60 · Phase 2 · secondary NCT01641809
  • 287 vs 279.4 30 mg · wk 84 · n 60 · Phase 2 · secondary NCT01641809
  • 201.4 vs 257.1 30 mg · wk 72 · n 60 · Phase 2 · secondary NCT01641809
  • 269.4 vs 263.8 30 mg · wk 60 · n 60 · Phase 2 · secondary NCT01641809
  • 241.6 vs 262.5 30 mg · wk 48 · n 60 · Phase 2 · secondary NCT01641809
  • 212.8 vs 221.5 30 mg · wk 40 · n 60 · Phase 2 · secondary NCT01641809
  • 213 vs 185.2 30 mg · wk 36 · n 60 · Phase 2 · secondary NCT01641809
  • 205.2 vs 197.4 30 mg · wk 32 · n 60 · Phase 2 · secondary NCT01641809
  • 188.1 vs 178.2 30 mg · wk 28 · n 60 · Phase 2 · secondary NCT01641809
  • 177.7 vs 166.4 30 mg · wk 26 · n 60 · Phase 2 · secondary NCT01641809
  • 180.9 vs 143.4 30 mg · wk 24 · n 60 · Phase 2 · secondary NCT01641809
  • 286.2 vs 281.7 60 mg · wk 96 · n 61 · Phase 2 · secondary NCT01641809
  • 278.1 vs 279.4 60 mg · wk 84 · n 61 · Phase 2 · secondary NCT01641809
  • 254 vs 257.1 60 mg · wk 72 · n 61 · Phase 2 · secondary NCT01641809
  • 266.1 vs 263.8 60 mg · wk 60 · n 61 · Phase 2 · secondary NCT01641809
  • 259 vs 262.5 60 mg · wk 48 · n 61 · Phase 2 · secondary NCT01641809
  • 212.3 vs 221.5 60 mg · wk 40 · n 61 · Phase 2 · secondary NCT01641809
  • 265 vs 185.2 60 mg · wk 36 · n 61 · Phase 2 · secondary NCT01641809
  • 209.9 vs 197.4 60 mg · wk 32 · n 61 · Phase 2 · secondary NCT01641809
  • 193.3 vs 178.2 60 mg · wk 28 · n 61 · Phase 2 · secondary NCT01641809
  • 194.7 vs 166.4 60 mg · wk 26 · n 61 · Phase 2 · secondary NCT01641809
  • 204 vs 143.4 60 mg · wk 24 · n 61 · Phase 2 · secondary NCT01641809
  • 269.4 vs 281.7 10 mg · wk 96 · n 60 · Phase 2 · secondary NCT01641809
  • 261.5 vs 279.4 10 mg · wk 84 · n 60 · Phase 2 · secondary NCT01641809
  • 232 vs 257.1 10 mg · wk 72 · n 60 · Phase 2 · secondary NCT01641809
  • 217.7 vs 263.8 10 mg · wk 60 · n 60 · Phase 2 · secondary NCT01641809
  • 235.1 vs 262.5 10 mg · wk 48 · n 60 · Phase 2 · secondary NCT01641809
  • 203.6 vs 221.5 10 mg · wk 40 · n 60 · Phase 2 · secondary NCT01641809
  • 192 vs 185.2 10 mg · wk 36 · n 60 · Phase 2 · secondary NCT01641809
  • 191.4 vs 197.4 10 mg · wk 32 · n 60 · Phase 2 · secondary NCT01641809
  • 205 vs 178.2 10 mg · wk 28 · n 60 · Phase 2 · secondary NCT01641809
  • 186.4 vs 166.4 10 mg · wk 26 · n 60 · Phase 2 · secondary NCT01641809
  • 172.5 vs 143.4 10 mg · wk 24 · n 60 · Phase 2 · secondary NCT01641809

HIV-1 RNA below 50 copies/mL (week 48)

ACC017
—Trial running · NCT07711223
Cabotegravir/​rilpivirine (Cabenuva)
94% vs 91%vs CAB 30 mg+ABC/3TCIM-Q4W · wk 32 · n 115NCT02120352
125 other results
  • 95% vs 91% IM-Q8W · wk 32 · n 115 · Phase 2 · primary NCT02120352
  • 80% vs 71% 30 mg · wk 48 · n 60 · Phase 2 · primary NCT01641809
  • 87% vs 71% 60 mg · wk 48 · n 61 · Phase 2 · primary NCT01641809
  • 80% vs 71% 10 mg · wk 48 · n 60 · Phase 2 · primary NCT01641809
  • 52% vs 0% 30 mg · wk 312 · n 60 · Phase 2 · secondary NCT01641809
  • 60% vs 0% 30 mg · wk 300 · n 60 · Phase 2 · secondary NCT01641809
  • 62% vs 0% 30 mg · wk 288 · n 60 · Phase 2 · secondary NCT01641809
  • 62% vs 0% 30 mg · wk 276 · n 60 · Phase 2 · secondary NCT01641809
  • 62% vs 0% 30 mg · wk 264 · n 60 · Phase 2 · secondary NCT01641809
  • 62% vs 0% 30 mg · wk 252 · n 60 · Phase 2 · secondary NCT01641809
  • 62% vs 0% 30 mg · wk 240 · n 60 · Phase 2 · secondary NCT01641809
  • 63% vs 0% 30 mg · wk 228 · n 60 · Phase 2 · secondary NCT01641809
  • 63% vs 0% 30 mg · wk 216 · n 60 · Phase 2 · secondary NCT01641809
  • 62% vs 0% 30 mg · wk 204 · n 60 · Phase 2 · secondary NCT01641809
  • 65% vs 0% 30 mg · wk 192 · n 60 · Phase 2 · secondary NCT01641809
  • 67% vs 0% 30 mg · wk 180 · n 60 · Phase 2 · secondary NCT01641809
  • 65% vs 0% 30 mg · wk 168 · n 60 · Phase 2 · secondary NCT01641809
  • 63% vs 0% 30 mg · wk 156 · n 60 · Phase 2 · secondary NCT01641809
  • 67% vs 0% 30 mg · wk 144 · n 60 · Phase 2 · secondary NCT01641809
  • 70% vs 0% 30 mg · wk 132 · n 60 · Phase 2 · secondary NCT01641809
  • 73% vs 0% 30 mg · wk 120 · n 60 · Phase 2 · secondary NCT01641809
  • 72% vs 0% 30 mg · wk 108 · n 60 · Phase 2 · secondary NCT01641809
  • 75% vs 63% 30 mg · wk 96 · n 60 · Phase 2 · secondary NCT01641809
  • 85% vs 83% 30 mg · wk 96 · n 53 · Phase 2 · secondary NCT01641809
  • 75% vs 68% 30 mg · wk 84 · n 60 · Phase 2 · secondary NCT01641809
  • 85% vs 89% 30 mg · wk 84 · n 53 · Phase 2 · secondary NCT01641809
  • 73% vs 68% 30 mg · wk 72 · n 60 · Phase 2 · secondary NCT01641809
  • 83% vs 89% 30 mg · wk 72 · n 53 · Phase 2 · secondary NCT01641809
  • 73% vs 68% 30 mg · wk 60 · n 60 · Phase 2 · secondary NCT01641809
  • 83% vs 89% 30 mg · wk 60 · n 53 · Phase 2 · secondary NCT01641809
  • 80% vs 71% 30 mg · wk 48 · n 60 · Phase 2 · secondary NCT01641809
  • 91% vs 94% 30 mg · wk 48 · n 53 · Phase 2 · secondary NCT01641809
  • 82% vs 68% 30 mg · wk 40 · n 60 · Phase 2 · secondary NCT01641809
  • 92% vs 89% 30 mg · wk 40 · n 53 · Phase 2 · secondary NCT01641809
  • 82% vs 71% 30 mg · wk 36 · n 60 · Phase 2 · secondary NCT01641809
  • 92% vs 94% 30 mg · wk 36 · n 53 · Phase 2 · secondary NCT01641809
  • 80% vs 69% 30 mg · wk 32 · n 60 · Phase 2 · secondary NCT01641809
  • 91% vs 91% 30 mg · wk 32 · n 53 · Phase 2 · secondary NCT01641809
  • 78% vs 69% 30 mg · wk 28 · n 60 · Phase 2 · secondary NCT01641809
  • 89% vs 91% 30 mg · wk 28 · n 53 · Phase 2 · secondary NCT01641809
  • 75% vs 66% 30 mg · wk 26 · n 60 · Phase 2 · secondary NCT01641809
  • 85% vs 87% 30 mg · wk 26 · n 53 · Phase 2 · secondary NCT01641809
  • 85% vs 74% 30 mg · wk 24 · n 60 · Phase 2 · secondary NCT01641809
  • 94% vs 96% 30 mg · wk 24 · n 53 · Phase 2 · secondary NCT01641809
  • 70% vs 0% 60 mg · wk 312 · n 61 · Phase 2 · secondary NCT01641809
  • 70% vs 0% 60 mg · wk 300 · n 61 · Phase 2 · secondary NCT01641809
  • 74% vs 0% 60 mg · wk 288 · n 61 · Phase 2 · secondary NCT01641809
  • 70% vs 0% 60 mg · wk 276 · n 61 · Phase 2 · secondary NCT01641809
  • 75% vs 0% 60 mg · wk 264 · n 61 · Phase 2 · secondary NCT01641809
  • 75% vs 0% 60 mg · wk 252 · n 61 · Phase 2 · secondary NCT01641809
  • 74% vs 0% 60 mg · wk 240 · n 61 · Phase 2 · secondary NCT01641809
  • 75% vs 0% 60 mg · wk 228 · n 61 · Phase 2 · secondary NCT01641809
  • 77% vs 0% 60 mg · wk 216 · n 61 · Phase 2 · secondary NCT01641809
  • 75% vs 0% 60 mg · wk 204 · n 61 · Phase 2 · secondary NCT01641809
  • 74% vs 0% 60 mg · wk 192 · n 61 · Phase 2 · secondary NCT01641809
  • 75% vs 0% 60 mg · wk 180 · n 61 · Phase 2 · secondary NCT01641809
  • 75% vs 0% 60 mg · wk 168 · n 61 · Phase 2 · secondary NCT01641809
  • 80% vs 0% 60 mg · wk 156 · n 61 · Phase 2 · secondary NCT01641809
  • 77% vs 0% 60 mg · wk 144 · n 61 · Phase 2 · secondary NCT01641809
  • 80% vs 0% 60 mg · wk 132 · n 61 · Phase 2 · secondary NCT01641809
  • 80% vs 0% 60 mg · wk 120 · n 61 · Phase 2 · secondary NCT01641809
  • 80% vs 0% 60 mg · wk 108 · n 61 · Phase 2 · secondary NCT01641809
  • 84% vs 63% 60 mg · wk 96 · n 61 · Phase 2 · secondary NCT01641809
  • 93% vs 83% 60 mg · wk 96 · n 55 · Phase 2 · secondary NCT01641809
  • 85% vs 68% 60 mg · wk 84 · n 61 · Phase 2 · secondary NCT01641809
  • 95% vs 89% 60 mg · wk 84 · n 55 · Phase 2 · secondary NCT01641809
  • 85% vs 68% 60 mg · wk 72 · n 61 · Phase 2 · secondary NCT01641809
  • 95% vs 89% 60 mg · wk 72 · n 55 · Phase 2 · secondary NCT01641809
  • 85% vs 68% 60 mg · wk 60 · n 61 · Phase 2 · secondary NCT01641809
  • 95% vs 89% 60 mg · wk 60 · n 55 · Phase 2 · secondary NCT01641809
  • 87% vs 71% 60 mg · wk 48 · n 61 · Phase 2 · secondary NCT01641809
  • 96% vs 94% 60 mg · wk 48 · n 55 · Phase 2 · secondary NCT01641809
  • 85% vs 68% 60 mg · wk 40 · n 61 · Phase 2 · secondary NCT01641809
  • 95% vs 89% 60 mg · wk 40 · n 55 · Phase 2 · secondary NCT01641809
  • 85% vs 71% 60 mg · wk 36 · n 61 · Phase 2 · secondary NCT01641809
  • 95% vs 94% 60 mg · wk 36 · n 55 · Phase 2 · secondary NCT01641809
  • 87% vs 69% 60 mg · wk 32 · n 61 · Phase 2 · secondary NCT01641809
  • 96% vs 91% 60 mg · wk 32 · n 55 · Phase 2 · secondary NCT01641809
  • 85% vs 69% 60 mg · wk 28 · n 61 · Phase 2 · secondary NCT01641809
  • 95% vs 91% 60 mg · wk 28 · n 55 · Phase 2 · secondary NCT01641809
  • 85% vs 66% 60 mg · wk 26 · n 61 · Phase 2 · secondary NCT01641809
  • 95% vs 87% 60 mg · wk 26 · n 55 · Phase 2 · secondary NCT01641809
  • 87% vs 74% 60 mg · wk 24 · n 61 · Phase 2 · secondary NCT01641809
  • 96% vs 96% 60 mg · wk 24 · n 55 · Phase 2 · secondary NCT01641809
  • 52% vs 0% 10 mg · wk 312 · n 60 · Phase 2 · secondary NCT01641809
  • 52% vs 0% 10 mg · wk 300 · n 60 · Phase 2 · secondary NCT01641809
  • 50% vs 0% 10 mg · wk 288 · n 60 · Phase 2 · secondary NCT01641809
  • 52% vs 0% 10 mg · wk 276 · n 60 · Phase 2 · secondary NCT01641809
  • 53% vs 0% 10 mg · wk 264 · n 60 · Phase 2 · secondary NCT01641809
  • 52% vs 0% 10 mg · wk 252 · n 60 · Phase 2 · secondary NCT01641809
  • 50% vs 0% 10 mg · wk 240 · n 60 · Phase 2 · secondary NCT01641809
  • 53% vs 0% 10 mg · wk 228 · n 60 · Phase 2 · secondary NCT01641809
  • 55% vs 0% 10 mg · wk 216 · n 60 · Phase 2 · secondary NCT01641809
  • 55% vs 0% 10 mg · wk 204 · n 60 · Phase 2 · secondary NCT01641809
  • 57% vs 0% 10 mg · wk 192 · n 60 · Phase 2 · secondary NCT01641809
  • 58% vs 0% 10 mg · wk 180 · n 60 · Phase 2 · secondary NCT01641809
  • 57% vs 0% 10 mg · wk 168 · n 60 · Phase 2 · secondary NCT01641809
  • 58% vs 0% 10 mg · wk 156 · n 60 · Phase 2 · secondary NCT01641809
  • 58% vs 0% 10 mg · wk 144 · n 60 · Phase 2 · secondary NCT01641809
  • 62% vs 0% 10 mg · wk 132 · n 60 · Phase 2 · secondary NCT01641809
  • 65% vs 0% 10 mg · wk 120 · n 60 · Phase 2 · secondary NCT01641809
  • 68% vs 0% 10 mg · wk 108 · n 60 · Phase 2 · secondary NCT01641809
  • 68% vs 63% 10 mg · wk 96 · n 60 · Phase 2 · secondary NCT01641809
  • 79% vs 83% 10 mg · wk 96 · n 52 · Phase 2 · secondary NCT01641809
  • 72% vs 68% 10 mg · wk 84 · n 60 · Phase 2 · secondary NCT01641809
  • 83% vs 89% 10 mg · wk 84 · n 52 · Phase 2 · secondary NCT01641809
  • 72% vs 68% 10 mg · wk 72 · n 60 · Phase 2 · secondary NCT01641809
  • 83% vs 89% 10 mg · wk 72 · n 52 · Phase 2 · secondary NCT01641809
  • 78% vs 68% 10 mg · wk 60 · n 60 · Phase 2 · secondary NCT01641809
  • 90% vs 89% 10 mg · wk 60 · n 52 · Phase 2 · secondary NCT01641809
  • 80% vs 71% 10 mg · wk 48 · n 60 · Phase 2 · secondary NCT01641809
  • 92% vs 94% 10 mg · wk 48 · n 52 · Phase 2 · secondary NCT01641809
  • 83% vs 68% 10 mg · wk 40 · n 60 · Phase 2 · secondary NCT01641809
  • 96% vs 89% 10 mg · wk 40 · n 52 · Phase 2 · secondary NCT01641809
  • 85% vs 71% 10 mg · wk 36 · n 60 · Phase 2 · secondary NCT01641809
  • 98% vs 94% 10 mg · wk 36 · n 52 · Phase 2 · secondary NCT01641809
  • 83% vs 69% 10 mg · wk 32 · n 60 · Phase 2 · secondary NCT01641809
  • 96% vs 91% 10 mg · wk 32 · n 52 · Phase 2 · secondary NCT01641809
  • 85% vs 69% 10 mg · wk 28 · n 60 · Phase 2 · secondary NCT01641809
  • 98% vs 91% 10 mg · wk 28 · n 52 · Phase 2 · secondary NCT01641809
  • 78% vs 66% 10 mg · wk 26 · n 60 · Phase 2 · secondary NCT01641809
  • 90% vs 87% 10 mg · wk 26 · n 52 · Phase 2 · secondary NCT01641809
  • 87% vs 74% 10 mg · wk 24 · n 60 · Phase 2 · secondary NCT01641809
  • 96% vs 96% 10 mg · wk 24 · n 52 · Phase 2 · secondary NCT01641809
  • 98% vs 100% Q2M · wk 48 · n 90 · Phase 2 · secondary NCT03639311

HIV-1 RNA 50 copies/mL or more (week 48)

ACC017
—Trial running · NCT07711223
Cabotegravir/​rilpivirine (Cabenuva)
0% vs 0%vs DTG + RPVQ2M · wk 48 · n 90NCT03639311

CD4 count, change (week 48)

ACC017
—Trial running · NCT07711223
Cabotegravir/​rilpivirine (Cabenuva)
270.6 vs 369.9vs CAB 30 mg+ABC/3TCIM-Q4W · wk 96 · n 108NCT02120352
36 other results
  • 263.7 vs 346.1 IM-Q4W · wk 32 · n 108 · Phase 2 · secondary NCT02120352
  • 257.5 vs 369.9 IM-Q8W · wk 96 · n 112 · Phase 2 · secondary NCT02120352
  • 264.4 vs 346.1 IM-Q8W · wk 32 · n 112 · Phase 2 · secondary NCT02120352
  • 267.5 vs 281.7 30 mg · wk 96 · n 60 · Phase 2 · secondary NCT01641809
  • 287 vs 279.4 30 mg · wk 84 · n 60 · Phase 2 · secondary NCT01641809
  • 201.4 vs 257.1 30 mg · wk 72 · n 60 · Phase 2 · secondary NCT01641809
  • 269.4 vs 263.8 30 mg · wk 60 · n 60 · Phase 2 · secondary NCT01641809
  • 241.6 vs 262.5 30 mg · wk 48 · n 60 · Phase 2 · secondary NCT01641809
  • 212.8 vs 221.5 30 mg · wk 40 · n 60 · Phase 2 · secondary NCT01641809
  • 213 vs 185.2 30 mg · wk 36 · n 60 · Phase 2 · secondary NCT01641809
  • 205.2 vs 197.4 30 mg · wk 32 · n 60 · Phase 2 · secondary NCT01641809
  • 188.1 vs 178.2 30 mg · wk 28 · n 60 · Phase 2 · secondary NCT01641809
  • 177.7 vs 166.4 30 mg · wk 26 · n 60 · Phase 2 · secondary NCT01641809
  • 180.9 vs 143.4 30 mg · wk 24 · n 60 · Phase 2 · secondary NCT01641809
  • 286.2 vs 281.7 60 mg · wk 96 · n 61 · Phase 2 · secondary NCT01641809
  • 278.1 vs 279.4 60 mg · wk 84 · n 61 · Phase 2 · secondary NCT01641809
  • 254 vs 257.1 60 mg · wk 72 · n 61 · Phase 2 · secondary NCT01641809
  • 266.1 vs 263.8 60 mg · wk 60 · n 61 · Phase 2 · secondary NCT01641809
  • 259 vs 262.5 60 mg · wk 48 · n 61 · Phase 2 · secondary NCT01641809
  • 212.3 vs 221.5 60 mg · wk 40 · n 61 · Phase 2 · secondary NCT01641809
  • 265 vs 185.2 60 mg · wk 36 · n 61 · Phase 2 · secondary NCT01641809
  • 209.9 vs 197.4 60 mg · wk 32 · n 61 · Phase 2 · secondary NCT01641809
  • 193.3 vs 178.2 60 mg · wk 28 · n 61 · Phase 2 · secondary NCT01641809
  • 194.7 vs 166.4 60 mg · wk 26 · n 61 · Phase 2 · secondary NCT01641809
  • 204 vs 143.4 60 mg · wk 24 · n 61 · Phase 2 · secondary NCT01641809
  • 269.4 vs 281.7 10 mg · wk 96 · n 60 · Phase 2 · secondary NCT01641809
  • 261.5 vs 279.4 10 mg · wk 84 · n 60 · Phase 2 · secondary NCT01641809
  • 232 vs 257.1 10 mg · wk 72 · n 60 · Phase 2 · secondary NCT01641809
  • 217.7 vs 263.8 10 mg · wk 60 · n 60 · Phase 2 · secondary NCT01641809
  • 235.1 vs 262.5 10 mg · wk 48 · n 60 · Phase 2 · secondary NCT01641809
  • 203.6 vs 221.5 10 mg · wk 40 · n 60 · Phase 2 · secondary NCT01641809
  • 192 vs 185.2 10 mg · wk 36 · n 60 · Phase 2 · secondary NCT01641809
  • 191.4 vs 197.4 10 mg · wk 32 · n 60 · Phase 2 · secondary NCT01641809
  • 205 vs 178.2 10 mg · wk 28 · n 60 · Phase 2 · secondary NCT01641809
  • 186.4 vs 166.4 10 mg · wk 26 · n 60 · Phase 2 · secondary NCT01641809
  • 172.5 vs 143.4 10 mg · wk 24 · n 60 · Phase 2 · secondary NCT01641809
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

ACC017
The mean decrease in the groups ranged from 1.44 to 2.34 log 10 copies/mL and none of the participants experienced viral breakthrough. A total of 86.11% of the participants had HIV-RNA of less than 50 copies/mL at day 29. NCT06719310 · Phase 1/2 · design grade: moderate · reviewed ClinicalTrials.gov result

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. ACC017: 0 of 4 rows · Cabotegravir/rilpivirine (Cabenuva): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricCabotegravir/​rilpivirine (Cabenuva)
Dropout rate
13.6%a
NCT04982445 · Phase 4 · registry result, not featured evidence
show 45 more results
—400 mg + 600 mg Q4W
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
—400 mg + 600 mg Q4W
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
—400 mg + 600 mg Q4W
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
1.1%400 mg + 600 mg Q4W
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
8.6%Direct to Injections (D2I)
NCT04542070 · Phase 3 · registry result, not featured evidence
13.1%Oral lead-in Phase (OLI)
NCT04542070 · Phase 3 · registry result, not featured evidence
—Q2M
NCT04542070 · Phase 3 · registry result, not featured evidence
6.5%
NCT04399551 · Phase 3 · registry result, not featured evidence
11.3%
NCT04001803 · Phase 3 · registry result, not featured evidence
1.3%CAB LA + VRC07-523LS
NCT03739996 · Phase 2 · registry result, not featured evidence · combination
—Step 2: CAB LA + VRC07-523LS
NCT03739996 · Phase 2 · registry result, not featured evidence · combination
—IM-Q4W
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
—IM-Q4W
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
—IM-Q8W
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
—IM-Q8W
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
15.6%Q2M
NCT03639311 · Phase 2 · registry result, not featured evidence · combination
11.7%30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
—30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
—30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
—30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
9.8%60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
—60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
—60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
—60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
13.3%10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
—10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
—10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
—10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
12.5%30 mg
NCT00920426 · Phase 2 · registry result, not featured evidence
—5 mg
NCT00920426 · Phase 2 · registry result, not featured evidence
15.2%30 mg
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 1 (C1) CAB200
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 1 (C1) CAB400
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 2 (C2) CAB200
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 2 (C2) CAB400
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 3 (C3) CAB200
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 3 (C3) CAB400
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 4 (C4) CAB200
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 4 (C4) CAB400
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 4h (C4h) CAB200 + r
NCT04484337 · Phase 1 · registry result, not featured evidence · combination
—Part 1: Cohort 4h (C4h) CAB400 + r
NCT04484337 · Phase 1 · registry result, not featured evidence · combination
—Part 2: Cohort 5 (C5) CAB200
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 2: Cohort 5 (C5) CAB400
NCT04484337 · Phase 1 · registry result, not featured evidence
—30 mg
NCT03149848 · Phase 1 · registry result, not featured evidence
—300 mg + 30 mg
NCT03149848 · Phase 1 · registry result, not featured evidence · combination
Discontinued due to AEs
—a
NCT04982445 · Phase 4 · registry result, not featured evidence
show 45 more results
—400 mg + 600 mg Q4W
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
—400 mg + 600 mg Q4W
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
—400 mg + 600 mg Q4W
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
—400 mg + 600 mg Q4W
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
1.1%Direct to Injections (D2I)
NCT04542070 · Phase 3 · registry result, not featured evidence
5.7%Oral lead-in Phase (OLI)
NCT04542070 · Phase 3 · registry result, not featured evidence
—Q2M
NCT04542070 · Phase 3 · registry result, not featured evidence
3.5%
NCT04399551 · Phase 3 · registry result, not featured evidence
4.3%
NCT04001803 · Phase 3 · registry result, not featured evidence
—CAB LA + VRC07-523LS
NCT03739996 · Phase 2 · registry result, not featured evidence · combination
—Step 2: CAB LA + VRC07-523LS
NCT03739996 · Phase 2 · registry result, not featured evidence · combination
—IM-Q4W
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
—IM-Q4W
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
—IM-Q8W
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
—IM-Q8W
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
1.1%Q2M
NCT03639311 · Phase 2 · registry result, not featured evidence · combination
1.7%30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
—30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
—30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
—30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
4.9%60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
—60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
—60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
—60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
0%10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
—10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
—10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
—10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
12.5%30 mg
NCT00920426 · Phase 2 · registry result, not featured evidence
—5 mg
NCT00920426 · Phase 2 · registry result, not featured evidence
—30 mg
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 1 (C1) CAB200
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 1 (C1) CAB400
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 2 (C2) CAB200
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 2 (C2) CAB400
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 3 (C3) CAB200
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 3 (C3) CAB400
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 4 (C4) CAB200
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 4 (C4) CAB400
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 4h (C4h) CAB200 + r
NCT04484337 · Phase 1 · registry result, not featured evidence · combination
—Part 1: Cohort 4h (C4h) CAB400 + r
NCT04484337 · Phase 1 · registry result, not featured evidence · combination
—Part 2: Cohort 5 (C5) CAB200
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 2: Cohort 5 (C5) CAB400
NCT04484337 · Phase 1 · registry result, not featured evidence
—30 mg
NCT03149848 · Phase 1 · registry result, not featured evidence
—300 mg + 30 mg
NCT03149848 · Phase 1 · registry result, not featured evidence · combination
Serious AEs
0%a
NCT04982445 · Phase 4 · registry result, not featured evidence
show 45 more results
0%400 mg + 600 mg Q4W
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
0%400 mg + 600 mg Q4W
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
1.1%400 mg + 600 mg Q4W
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
—400 mg + 600 mg Q4W
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
3.6%Direct to Injections (D2I)
NCT04542070 · Phase 3 · registry result, not featured evidence
6.3%Oral lead-in Phase (OLI)
NCT04542070 · Phase 3 · registry result, not featured evidence
3.4%Q2M
NCT04542070 · Phase 3 · registry result, not featured evidence
4%
NCT04399551 · Phase 3 · registry result, not featured evidence
7.8%
NCT04001803 · Phase 3 · registry result, not featured evidence
—CAB LA + VRC07-523LS
NCT03739996 · Phase 2 · registry result, not featured evidence · combination
12.7%Step 2: CAB LA + VRC07-523LS
NCT03739996 · Phase 2 · registry result, not featured evidence · combination
27%IM-Q4W
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
10%IM-Q4W
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
27%IM-Q8W
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
26.5%IM-Q8W
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
11.1%Q2M
NCT03639311 · Phase 2 · registry result, not featured evidence · combination
—30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
0%30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
9.4%30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
17%30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
—60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
3.3%60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
9.1%60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
9.8%60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
—10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
3.3%10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
9.6%10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
15.2%10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
0%30 mg
NCT00920426 · Phase 2 · registry result, not featured evidence
0%5 mg
NCT00920426 · Phase 2 · registry result, not featured evidence
0%30 mg
NCT04484337 · Phase 1 · registry result, not featured evidence
0%Part 1: Cohort 1 (C1) CAB200
NCT04484337 · Phase 1 · registry result, not featured evidence
0%Part 1: Cohort 1 (C1) CAB400
NCT04484337 · Phase 1 · registry result, not featured evidence
0%Part 1: Cohort 2 (C2) CAB200
NCT04484337 · Phase 1 · registry result, not featured evidence
0%Part 1: Cohort 2 (C2) CAB400
NCT04484337 · Phase 1 · registry result, not featured evidence
0%Part 1: Cohort 3 (C3) CAB200
NCT04484337 · Phase 1 · registry result, not featured evidence
12.5%Part 1: Cohort 3 (C3) CAB400
NCT04484337 · Phase 1 · registry result, not featured evidence
0%Part 1: Cohort 4 (C4) CAB200
NCT04484337 · Phase 1 · registry result, not featured evidence
0%Part 1: Cohort 4 (C4) CAB400
NCT04484337 · Phase 1 · registry result, not featured evidence
0%Part 1: Cohort 4h (C4h) CAB200 + r
NCT04484337 · Phase 1 · registry result, not featured evidence · combination
0%Part 1: Cohort 4h (C4h) CAB400 + r
NCT04484337 · Phase 1 · registry result, not featured evidence · combination
0%Part 2: Cohort 5 (C5) CAB200
NCT04484337 · Phase 1 · registry result, not featured evidence
0%Part 2: Cohort 5 (C5) CAB400
NCT04484337 · Phase 1 · registry result, not featured evidence
0%30 mg
NCT03149848 · Phase 1 · registry result, not featured evidence
7.1%300 mg + 30 mg
NCT03149848 · Phase 1 · registry result, not featured evidence · combination
Most frequent reported AEs
a
injection site discomfort 13.6%
injection site pain 13.6%
fatigue 2.3%
NCT04982445 · Phase 4 · registry result, not featured evidence
show 40 more results
400 mg + 600 mg Q4W
injection site pain 32.3%
injection site nodule 9.7%
injection site induration 2.2%
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
400 mg + 600 mg Q4W
injection site pain 74.2%
injection site nodule 64.5%
injection site erythema 51.6%
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
400 mg + 600 mg Q4W
injection site pain 30.9%
injection site nodule 3.2%
injection site pruritus 2.1%
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
injection site pain 65.2%
covid-19 17.9%
headache 12.5%
NCT04542070 · Phase 3 · registry result, not featured evidence
injection site pain 60.6%
covid-19 19.4%
injection site induration 11.4%
NCT04542070 · Phase 3 · registry result, not featured evidence
Q2M
injection site pain 37.9%
covid-19 14.5%
arthralgia 0%
NCT04542070 · Phase 3 · registry result, not featured evidence
injection site pain 80.2%
covid-19 18.4%
injection site induration 11.2%
NCT04399551 · Phase 3 · registry result, not featured evidence
injection site pain 55.7%
injection site discomfort 26.1%
fatigue 20%
NCT04001803 · Phase 3 · registry result, not featured evidence
creatinine renal clearance decreased 19.7%
lipase increased 11.3%
chills 7%
NCT03739996 · Phase 2 · registry result, not featured evidence · combination
IM-Q4W
injection site pain 99.1%
injection site nodule 49.6%
nasopharyngitis 47%
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
IM-Q4W
injection site pain 80%
injection site nodule 50%
nasopharyngitis 50%
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
IM-Q8W
injection site pain 96.5%
nasopharyngitis 47%
injection site nodule 40%
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
IM-Q8W
injection site pain 91.2%
injection site nodule 35.3%
covid-19 26.5%
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
Q2M
injection site pain 74.4%
covid-19 33.3%
upper respiratory tract infection 17.8%
NCT03639311 · Phase 2 · registry result, not featured evidence · combination
30 mg
headache 21.7%
nausea 18.3%
upper respiratory tract infection 13.3%
NCT01641809 · Phase 2 · registry result, not featured evidence
30 mg
upper respiratory tract infection 26.4%
diarrhoea 13.2%
rash 11.3%
NCT01641809 · Phase 2 · registry result, not featured evidence
30 mg
upper respiratory tract infection 31.9%
back pain 12.8%
oropharyngeal pain 12.8%
NCT01641809 · Phase 2 · registry result, not featured evidence
60 mg
headache 21.3%
diarrhoea 18%
nausea 18%
NCT01641809 · Phase 2 · registry result, not featured evidence
60 mg
upper respiratory tract infection 21.8%
nausea 14.5%
bronchitis 10.9%
NCT01641809 · Phase 2 · registry result, not featured evidence
60 mg
upper respiratory tract infection 27.5%
anxiety 11.8%
sinusitis 11.8%
NCT01641809 · Phase 2 · registry result, not featured evidence
10 mg
nausea 23.3%
headache 21.7%
diarrhoea 16.7%
NCT01641809 · Phase 2 · registry result, not featured evidence
10 mg
upper respiratory tract infection 17.3%
depression 9.6%
diarrhoea 9.6%
NCT01641809 · Phase 2 · registry result, not featured evidence
10 mg
diarrhoea 13%
nasopharyngitis 10.9%
gonorrhoea 8.7%
NCT01641809 · Phase 2 · registry result, not featured evidence
30 mg
dizziness 37.5% (placebo 0%)
dyspepsia 25% (placebo 0%)
headache 25% (placebo 0%)
NCT00920426 · Phase 2 · registry result, not featured evidence
5 mg
abdominal pain 0% (placebo 0%)
abnormal dreams 0% (placebo 0%)
blood bilirubin increased 0% (placebo 50%)
NCT00920426 · Phase 2 · registry result, not featured evidence
30 mg
atrioventricular block first degree 7.7%
decreased appetite 7.7%
headache 7.7%
NCT04484337 · Phase 1 · registry result, not featured evidence
injection site pain 100%
aspartate aminotransferase increased 50%
blood creatine phosphokinase increased 50%
NCT04484337 · Phase 1 · registry result, not featured evidence
injection site pain 100%
injection site nodule 55.6%
injection site erythema 44.4%
NCT04484337 · Phase 1 · registry result, not featured evidence
injection site haemorrhage 100%
injection site nodule 100%
injection site pain 100%
NCT04484337 · Phase 1 · registry result, not featured evidence
injection site erythema 72.7%
injection site pain 72.7%
injection site induration 45.5%
NCT04484337 · Phase 1 · registry result, not featured evidence
injection site induration 100%
injection site pain 100%
injection site bruising 50%
NCT04484337 · Phase 1 · registry result, not featured evidence
injection site pain 75%
headache 37.5%
injection site swelling 37.5%
NCT04484337 · Phase 1 · registry result, not featured evidence
catheter site bruise 50%
injection site erythema 50%
injection site induration 50%
NCT04484337 · Phase 1 · registry result, not featured evidence
injection site erythema 100%
injection site pain 94.4%
headache 77.8%
NCT04484337 · Phase 1 · registry result, not featured evidence
injection site erythema 100%
injection site pain 100%
injection site pruritus 87.5%
NCT04484337 · Phase 1 · registry result, not featured evidence · combination
injection site erythema 100%
injection site pain 100%
injection site warmth 88.9%
NCT04484337 · Phase 1 · registry result, not featured evidence · combination
accident 100%
injection site nodule 100%
injection site pain 100%
NCT04484337 · Phase 1 · registry result, not featured evidence
injection site pain 100%
injection site swelling 70%
headache 60%
NCT04484337 · Phase 1 · registry result, not featured evidence
30 mg
blood creatine phosphokinase increased 6.7%
contusion 6.7%
body temperature increased 0%
NCT03149848 · Phase 1 · registry result, not featured evidence
300 mg + 30 mg
body temperature increased 7.1%
headache 7.1%
hyperkeratosis 7.1%
NCT03149848 · Phase 1 · registry result, not featured evidence · combination

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Cabotegravir/rilpivirine (Cabenuva)

HIV-1 RNA Less Than 50 Copies Per 100% (n=93) @ 4wk400 mg + 600 mg Q4W
responder rate · % of participants
No placebo or comparator arm
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
show 2 more results
99% (n=93) @ 8wk400 mg + 600 mg Q4W
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
90% (n=93) @ 12wk400 mg + 600 mg Q4W
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
HIV-1 RNA Ge50 Copies 0% (n=93) @ 4wk400 mg + 600 mg Q4W
responder rate · % of participants
No placebo or comparator arm
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
show 2 more results
1.1% (n=93) @ 8wk400 mg + 600 mg Q4W
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
2.2% (n=93) @ 12wk400 mg + 600 mg Q4W
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
Virologic Failure 0% (n=93)400 mg + 600 mg Q4W
responder rate · % of participants
No placebo or comparator arm
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
show 1 more result
0% (n=115)
NCT04001803 · Phase 3 · registry result, not featured evidence
HIV-1 RNA Less Than 50 Copies 99% (n=430) @ 4.33wk
responder rate · % of participants
No placebo or comparator arm
NCT04399551 · Phase 3 · registry result, not featured evidence
show 4 more results
96% (n=430) @ 8.67wk
NCT04399551 · Phase 3 · registry result, not featured evidence
93% (n=430) @ 17.33wk
NCT04399551 · Phase 3 · registry result, not featured evidence
86% (n=430) @ 34.67wk
NCT04399551 · Phase 3 · registry result, not featured evidence
87% (n=430) @ 52wk
NCT04399551 · Phase 3 · registry result, not featured evidence
Virologic Failure 0% (n=430) @ 4.33wk
event count · % of participants
No placebo or comparator arm
NCT04399551 · Phase 3 · registry result, not featured evidence · converted to % from 0 Participants as posted
show 6 more results
0% (n=430) @ 8.67wk*
NCT04399551 · Phase 3 · registry result, not featured evidence · converted to % from 0 Participants as posted
0% (n=430) @ 17.33wk*
NCT04399551 · Phase 3 · registry result, not featured evidence · converted to % from 0 Participants as posted
0% (n=430) @ 26wk*
NCT04399551 · Phase 3 · registry result, not featured evidence · converted to % from 0 Participants as posted
0% (n=430) @ 34.67wk*
NCT04399551 · Phase 3 · registry result, not featured evidence · converted to % from 0 Participants as posted
0.2% (n=430) @ 43.33wk*
NCT04399551 · Phase 3 · registry result, not featured evidence · converted to % from 1 Participants as posted
0% (n=430) @ 52wk*
NCT04399551 · Phase 3 · registry result, not featured evidence · converted to % from 0 Participants as posted
HIV-1 RNA LT 50 Copies 93.9% (n=115) @ 4.33wk
responder rate · % of participants
No placebo or comparator arm
NCT04001803 · Phase 3 · registry result, not featured evidence
show 25 more results
94.8% (n=115) @ 8.67wk
NCT04001803 · Phase 3 · registry result, not featured evidence
91.3% (n=115) @ 17.33wk
NCT04001803 · Phase 3 · registry result, not featured evidence
90.4% (n=115) @ 26wk
NCT04001803 · Phase 3 · registry result, not featured evidence
88.7% (n=115) @ 34.67wk
NCT04001803 · Phase 3 · registry result, not featured evidence
87.8% (n=115) @ 43.33wk
NCT04001803 · Phase 3 · registry result, not featured evidence
88.7% (n=115) @ 52wk
NCT04001803 · Phase 3 · registry result, not featured evidence
96% (n=115) @ 4.33wk
NCT04001803 · Phase 3 · registry result, not featured evidence
100% (n=115) @ 8.67wk
NCT04001803 · Phase 3 · registry result, not featured evidence
98% (n=115) @ 17.33wk
NCT04001803 · Phase 3 · registry result, not featured evidence
100% (n=115) @ 26wk
NCT04001803 · Phase 3 · registry result, not featured evidence
100% (n=115) @ 34.67wk
NCT04001803 · Phase 3 · registry result, not featured evidence
99% (n=115) @ 43.33wk
NCT04001803 · Phase 3 · registry result, not featured evidence
100% (n=115) @ 52wk
NCT04001803 · Phase 3 · registry result, not featured evidence
100% (n=115) @ 56.33wk
NCT04001803 · Phase 3 · registry result, not featured evidence
100% (n=115) @ 65wk
NCT04001803 · Phase 3 · registry result, not featured evidence
99% (n=115) @ 69.33wk
NCT04001803 · Phase 3 · registry result, not featured evidence
100% (n=115) @ 78wk
NCT04001803 · Phase 3 · registry result, not featured evidence
100% (n=115) @ 82.33wk
NCT04001803 · Phase 3 · registry result, not featured evidence
100% (n=115) @ 91wk
NCT04001803 · Phase 3 · registry result, not featured evidence
100% (n=115) @ 95.33wk
NCT04001803 · Phase 3 · registry result, not featured evidence
100% (n=115) @ 104wk
NCT04001803 · Phase 3 · registry result, not featured evidence
100% (n=115) @ 108.33wk
NCT04001803 · Phase 3 · registry result, not featured evidence
100% (n=115) @ 117wk
NCT04001803 · Phase 3 · registry result, not featured evidence
100% (n=115) @ 121.33wk
NCT04001803 · Phase 3 · registry result, not featured evidence
100% (n=115) @ 130wk
NCT04001803 · Phase 3 · registry result, not featured evidence
Virologic Failure 0.07 Cumulative probability @ 44wk
absolute value · Cumulative probability
No placebo or comparator arm
NCT03739996 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
0.04 Cumulative probability @ 24wk
NCT03739996 · Phase 2 · registry result, not featured evidence · combination
Treatment Failure 0.14 Cumulative probability @ 44wk
absolute value · Cumulative probability
No placebo or comparator arm
NCT03739996 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
0.2 Cumulative probability @ 44wk
NCT03739996 · Phase 2 · registry result, not featured evidence · combination
Virologic Failure Rate 50 0.13 Cumulative probability @ 44wk
absolute value · Cumulative probability
No placebo or comparator arm
NCT03739996 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
0.12 Cumulative probability @ 24wk
NCT03739996 · Phase 2 · registry result, not featured evidence · combination
Virologic Failure Rate 50 9.9% (n=71) @ 44wk
event count · % of participants
No placebo or comparator arm
HIV-1 RNA ≥ 50 copies/mL on treatment
NCT03739996 · Phase 2 · registry result, not featured evidence · combination · converted to % from 7 Participants as posted
Virologic Response 50 Copies Snapshot 81.7% (n=71) @ 44wk
responder rate · % of participants
No placebo or comparator arm
HIV-1 RNA < 50 copies/mL on treatment
NCT03739996 · Phase 2 · registry result, not featured evidence · combination · converted to % from 58 Participants as posted
HIV-1 RNA Less Than 50 Copies 94% (n=115) vs 91% (n=56) CAB 30 mg+ABC/3TC @ 32wkIM-Q4W
responder rate · % of participants
Maintenance
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
show 125 more results
95% (n=115) vs 91% (n=56) CAB 30 mg+ABC/3TC @ 32wkIM-Q8W
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
80% (n=60) vs 71% (n=62) Efavirenz @ 48wk30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
85% (n=60) vs 74% (n=62) Efavirenz @ 24wk30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
75% (n=60) vs 66% (n=62) Efavirenz @ 26wk30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
78% (n=60) vs 69% (n=62) Efavirenz @ 28wk30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
80% (n=60) vs 69% (n=62) Efavirenz @ 32wk30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
82% (n=60) vs 71% (n=62) Efavirenz @ 36wk30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
82% (n=60) vs 68% (n=62) Efavirenz @ 40wk30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
80% (n=60) vs 71% (n=62) Efavirenz @ 48wk30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
73% (n=60) vs 68% (n=62) Efavirenz @ 60wk30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
73% (n=60) vs 68% (n=62) Efavirenz @ 72wk30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
75% (n=60) vs 68% (n=62) Efavirenz @ 84wk30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
75% (n=60) vs 63% (n=62) Efavirenz @ 96wk30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
72% (n=60) vs 0% (n=62) Efavirenz @ 108wk30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
73% (n=60) vs 0% (n=62) Efavirenz @ 120wk30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
70% (n=60) vs 0% (n=62) Efavirenz @ 132wk30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
67% (n=60) vs 0% (n=62) Efavirenz @ 144wk30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
63% (n=60) vs 0% (n=62) Efavirenz @ 156wk30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
65% (n=60) vs 0% (n=62) Efavirenz @ 168wk30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
67% (n=60) vs 0% (n=62) Efavirenz @ 180wk30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
65% (n=60) vs 0% (n=62) Efavirenz @ 192wk30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
62% (n=60) vs 0% (n=62) Efavirenz @ 204wk30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
63% (n=60) vs 0% (n=62) Efavirenz @ 216wk30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
63% (n=60) vs 0% (n=62) Efavirenz @ 228wk30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
62% (n=60) vs 0% (n=62) Efavirenz @ 240wk30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
62% (n=60) vs 0% (n=62) Efavirenz @ 252wk30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
62% (n=60) vs 0% (n=62) Efavirenz @ 264wk30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
62% (n=60) vs 0% (n=62) Efavirenz @ 276wk30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
62% (n=60) vs 0% (n=62) Efavirenz @ 288wk30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
60% (n=60) vs 0% (n=62) Efavirenz @ 300wk30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
52% (n=60) vs 0% (n=62) Efavirenz @ 312wk30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
94% (n=53) vs 96% (n=47) Efavirenz @ 24wk30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
85% (n=53) vs 87% (n=47) Efavirenz @ 26wk30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
89% (n=53) vs 91% (n=47) Efavirenz @ 28wk30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
91% (n=53) vs 91% (n=47) Efavirenz @ 32wk30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
92% (n=53) vs 94% (n=47) Efavirenz @ 36wk30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
92% (n=53) vs 89% (n=47) Efavirenz @ 40wk30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
91% (n=53) vs 94% (n=47) Efavirenz @ 48wk30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
83% (n=53) vs 89% (n=47) Efavirenz @ 60wk30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
83% (n=53) vs 89% (n=47) Efavirenz @ 72wk30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
85% (n=53) vs 89% (n=47) Efavirenz @ 84wk30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
85% (n=53) vs 83% (n=47) Efavirenz @ 96wk30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
87% (n=61) vs 71% (n=62) Efavirenz @ 48wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
87% (n=61) vs 74% (n=62) Efavirenz @ 24wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
85% (n=61) vs 66% (n=62) Efavirenz @ 26wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
85% (n=61) vs 69% (n=62) Efavirenz @ 28wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
87% (n=61) vs 69% (n=62) Efavirenz @ 32wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
85% (n=61) vs 71% (n=62) Efavirenz @ 36wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
85% (n=61) vs 68% (n=62) Efavirenz @ 40wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
87% (n=61) vs 71% (n=62) Efavirenz @ 48wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
85% (n=61) vs 68% (n=62) Efavirenz @ 60wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
85% (n=61) vs 68% (n=62) Efavirenz @ 72wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
85% (n=61) vs 68% (n=62) Efavirenz @ 84wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
84% (n=61) vs 63% (n=62) Efavirenz @ 96wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
80% (n=61) vs 0% (n=62) Efavirenz @ 108wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
80% (n=61) vs 0% (n=62) Efavirenz @ 120wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
80% (n=61) vs 0% (n=62) Efavirenz @ 132wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
77% (n=61) vs 0% (n=62) Efavirenz @ 144wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
80% (n=61) vs 0% (n=62) Efavirenz @ 156wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
75% (n=61) vs 0% (n=62) Efavirenz @ 168wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
75% (n=61) vs 0% (n=62) Efavirenz @ 180wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
74% (n=61) vs 0% (n=62) Efavirenz @ 192wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
75% (n=61) vs 0% (n=62) Efavirenz @ 204wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
77% (n=61) vs 0% (n=62) Efavirenz @ 216wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
75% (n=61) vs 0% (n=62) Efavirenz @ 228wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
74% (n=61) vs 0% (n=62) Efavirenz @ 240wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
75% (n=61) vs 0% (n=62) Efavirenz @ 252wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
75% (n=61) vs 0% (n=62) Efavirenz @ 264wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
70% (n=61) vs 0% (n=62) Efavirenz @ 276wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
74% (n=61) vs 0% (n=62) Efavirenz @ 288wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
70% (n=61) vs 0% (n=62) Efavirenz @ 300wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
70% (n=61) vs 0% (n=62) Efavirenz @ 312wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
96% (n=55) vs 96% (n=47) Efavirenz @ 24wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
95% (n=55) vs 87% (n=47) Efavirenz @ 26wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
95% (n=55) vs 91% (n=47) Efavirenz @ 28wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
96% (n=55) vs 91% (n=47) Efavirenz @ 32wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
95% (n=55) vs 94% (n=47) Efavirenz @ 36wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
95% (n=55) vs 89% (n=47) Efavirenz @ 40wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
96% (n=55) vs 94% (n=47) Efavirenz @ 48wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
95% (n=55) vs 89% (n=47) Efavirenz @ 60wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
95% (n=55) vs 89% (n=47) Efavirenz @ 72wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
95% (n=55) vs 89% (n=47) Efavirenz @ 84wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
93% (n=55) vs 83% (n=47) Efavirenz @ 96wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
80% (n=60) vs 71% (n=62) Efavirenz @ 48wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
87% (n=60) vs 74% (n=62) Efavirenz @ 24wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
78% (n=60) vs 66% (n=62) Efavirenz @ 26wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
85% (n=60) vs 69% (n=62) Efavirenz @ 28wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
83% (n=60) vs 69% (n=62) Efavirenz @ 32wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
85% (n=60) vs 71% (n=62) Efavirenz @ 36wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
83% (n=60) vs 68% (n=62) Efavirenz @ 40wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
80% (n=60) vs 71% (n=62) Efavirenz @ 48wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
78% (n=60) vs 68% (n=62) Efavirenz @ 60wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
72% (n=60) vs 68% (n=62) Efavirenz @ 72wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
72% (n=60) vs 68% (n=62) Efavirenz @ 84wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
68% (n=60) vs 63% (n=62) Efavirenz @ 96wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
68% (n=60) vs 0% (n=62) Efavirenz @ 108wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
65% (n=60) vs 0% (n=62) Efavirenz @ 120wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
62% (n=60) vs 0% (n=62) Efavirenz @ 132wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
58% (n=60) vs 0% (n=62) Efavirenz @ 144wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
58% (n=60) vs 0% (n=62) Efavirenz @ 156wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
57% (n=60) vs 0% (n=62) Efavirenz @ 168wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
58% (n=60) vs 0% (n=62) Efavirenz @ 180wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
57% (n=60) vs 0% (n=62) Efavirenz @ 192wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
55% (n=60) vs 0% (n=62) Efavirenz @ 204wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
55% (n=60) vs 0% (n=62) Efavirenz @ 216wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
53% (n=60) vs 0% (n=62) Efavirenz @ 228wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
50% (n=60) vs 0% (n=62) Efavirenz @ 240wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
52% (n=60) vs 0% (n=62) Efavirenz @ 252wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
53% (n=60) vs 0% (n=62) Efavirenz @ 264wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
52% (n=60) vs 0% (n=62) Efavirenz @ 276wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
50% (n=60) vs 0% (n=62) Efavirenz @ 288wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
52% (n=60) vs 0% (n=62) Efavirenz @ 300wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
52% (n=60) vs 0% (n=62) Efavirenz @ 312wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
96% (n=52) vs 96% (n=47) Efavirenz @ 24wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
90% (n=52) vs 87% (n=47) Efavirenz @ 26wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
98% (n=52) vs 91% (n=47) Efavirenz @ 28wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
96% (n=52) vs 91% (n=47) Efavirenz @ 32wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
98% (n=52) vs 94% (n=47) Efavirenz @ 36wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
96% (n=52) vs 89% (n=47) Efavirenz @ 40wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
92% (n=52) vs 94% (n=47) Efavirenz @ 48wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
90% (n=52) vs 89% (n=47) Efavirenz @ 60wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
83% (n=52) vs 89% (n=47) Efavirenz @ 72wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
83% (n=52) vs 89% (n=47) Efavirenz @ 84wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
79% (n=52) vs 83% (n=47) Efavirenz @ 96wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
98% (n=90) vs 100% (n=7) DTG + RPV @ 48wkQ2M
NCT03639311 · Phase 2 · registry result, not featured evidence · combination

+ 172 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ACC017's landscape · Cabotegravir/rilpivirine (Cabenuva)'s landscape